{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:56:01Z","timestamp":1791536161271,"version":"4.3.4"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01250"],"award-info":[{"award-number":["PI17\/01250"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007509","name":"Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica","doi-asserted-by":"publisher","award":["201\/2013"],"award-info":[{"award-number":["201\/2013"]}],"id":[{"id":"10.13039\/501100007509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0856-9","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T09:15:43Z","timestamp":1531300543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Alpha-1 antitrypsin deficiency: outstanding questions and future directions"],"prefix":"10.1186","volume":"13","author":[{"given":"Mar\u00eda","family":"Torres-Dur\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Barrecheguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Martinez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Baloira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Mercedes","family":"Navarro-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ba\u00f1uls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Magall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-2965","authenticated-orcid":false,"given":"Francisco","family":"Das\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"856_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","volume":"185","author":"JK Stoller","year":"2012","unstructured":"Stoller JK, Aboussouan LS. A review of \u03b11-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246\u201359.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"856_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/15412555.2013.763782","volume":"10","author":"JK Stoller","year":"2013","unstructured":"Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD. 2013;10(1):26\u201334.","journal-title":"COPD."},{"key":"856_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1183\/09031936.00111213","volume":"43","author":"L Tan","year":"2014","unstructured":"Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, et al. Circulating polymers in \u03b11-antitrypsin deficiency. Eur Respir J. 2014;43:1501\u20134.","journal-title":"Eur Respir J"},{"key":"856_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nsb1196-910","volume":"3","author":"PR Elliott","year":"1996","unstructured":"Elliott PR, Stein PE, Bilton D, Carrell RW, Lomas DA. Structural explanation for the deficiency of S alpha 1-antitrypsin. Nat Struct Biol. 1996;3:910\u20131.","journal-title":"Nat Struct Biol"},{"key":"856_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1172\/JCI4874","volume":"103","author":"R Mahadeva","year":"1999","unstructured":"Mahadeva R, Chang WS, Dafforn TR, Oakley DJ, Foreman RC, Calvin J, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest. 1999;103:999\u20131006.","journal-title":"J Clin Invest"},{"issue":"1","key":"856_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/15412555.2013.764401","volume":"10","author":"DA Lomas","year":"2013","unstructured":"Lomas DA. Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency. COPD. 2013;10(1):17\u201325.","journal-title":"COPD"},{"key":"856_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1586\/ers.13.20","volume":"7","author":"JA Brebner","year":"2013","unstructured":"Brebner JA, Stockley R. Recent advances in \u03b1-1-antitrypsin deficiency-related lung disease. Expert Rev Respir Med. 2013;7:213\u201329.","journal-title":"Expert Rev Respir Med"},{"key":"856_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/joim.12239","volume":"276","author":"F de Serres","year":"2014","unstructured":"de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 2014;276:311\u201335.","journal-title":"J Intern Med"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2147\/COPD.S137852","volume":"12","author":"I Blanco","year":"2017","unstructured":"Blanco I, Bueno P, Diego I, P\u00e9rez-Holanda S, Lara B, Casas-Maldonado F, et al. Alpha-1 antitrypsin pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide. Int J Chron Obstruct Pulmon Dis. 2017;12:1683\u201394.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"856_CR10","first-page":"253","volume":"116","author":"M Hadzik-Blaszczyk","year":"2018","unstructured":"Hadzik-Blaszczyk M, Zdral A, Zielonka TM, Rozy A, Krupa R, Falkowski A, et al. SERPINA1 gene variants in granulomatosis with polyangiitis. Adv Exp Med Biol. 2018;116:253\u201310.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"856_CR11","doi-asserted-by":"publisher","first-page":"S297","DOI":"10.1513\/AnnalsATS.201509-634KV","volume":"13","author":"C McCarthy","year":"2016","unstructured":"McCarthy C, Reeves EP, McElvaney NG. The role of neutrophils in alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(4):S297\u2013304.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"856_CR12","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1513\/AnnalsATS.201510-671KV","volume":"13","author":"MG Cosio","year":"2016","unstructured":"Cosio MG, Bazzan E, Rigobello C, Tin\u00e8 M, Turato G, Baraldo S, et al. Alpha-1 antitrypsin deficiency: beyond the protease\/antiprotease paradigm. Ann Am Thorac Soc. 2016;13(4):S305\u201310.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"856_CR13","doi-asserted-by":"publisher","first-page":"S280","DOI":"10.1513\/AnnalsATS.201507-468KV","volume":"13","author":"S Janciauskiene","year":"2016","unstructured":"Janciauskiene S, Welte T. Well-known and less well-known functions of alpha-1 antitrypsin. Its role in chronic obstructive pulmonary disease and other disease developments. Ann Am Thorac Soc. 2016;13(4):S280\u20138.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00005-012-0162-5","volume":"60","author":"DA Bergin","year":"2012","unstructured":"Bergin DA, Hurley K, McElvaney NG, Reeves EP. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp. 2012;60:81\u201397.","journal-title":"Arch Immunol Ther Exp"},{"key":"856_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1753465812457113","volume":"6","author":"FJ de Serres","year":"2012","unstructured":"de Serres FJ, Blanco I. Prevalence of \u03b11-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6:277\u201395.","journal-title":"Ther Adv Respir Dis"},{"key":"856_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1289\/ehp.6511","volume":"111","author":"FJ de Serres","year":"2003","unstructured":"de Serres FJ. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect. 2003;111:1851\u20134.","journal-title":"Environ Health Perspect"},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/COPD.S125389","volume":"12","author":"I Blanco","year":"2017","unstructured":"Blanco I, Bueno P, Diego I, P\u00e9rez-Holanda S, Casas-Maldonado F, Esquinas C, et al. Alpha-1 antitrypsin pi*Z gene frequency and pi*ZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"856_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.07-1001","volume":"133","author":"DK Hogarth","year":"2008","unstructured":"Hogarth DK, Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest. 2008;133:981\u20138.","journal-title":"Chest"},{"key":"856_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-3-16","volume":"3","author":"L Fregonese","year":"2008","unstructured":"Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"856_CR20","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1513\/AnnalsATS.201510-684KV","volume":"13","author":"RA Sandhaus","year":"2016","unstructured":"Sandhaus RA. Randomized, placebo-controlled trials in alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(4):S370\u20133.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1753465810373911","volume":"4","author":"AR Tonelli","year":"2010","unstructured":"Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis. 2010;4:289\u2013312.","journal-title":"Ther Adv Respir Dis"},{"key":"856_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/adc.85.1.2","volume":"85","author":"RA Primhak","year":"2001","unstructured":"Primhak RA, Tanner MS. Alpha-1 antitrypsin deficiency. Arch Dis Child. 2001;85:2\u20135.","journal-title":"Arch Dis Child"},{"issue":"1","key":"856_CR23","first-page":"34","volume":"30","author":"S Eriksson","year":"1999","unstructured":"Eriksson S. Alpha 1-antitrypsin deficiency. J Hepatol. 1999;30(1):34\u20139.","journal-title":"J Hepatol"},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1034\/j.1399-0004.2003.00143.x","volume":"64","author":"FJ de Serres","year":"2003","unstructured":"de Serres FJ, Blanco I, Fern\u00e1ndez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia\/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382\u201397.","journal-title":"Clin Genet"},{"key":"856_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2298\/SARH1410547R","volume":"142","author":"N Radlovi\u0107","year":"2014","unstructured":"Radlovi\u0107 N, Lekovi\u0107 Z, Radlovi\u0107 V, Simi\u0107 D, Topic A, Risti\u0107 D, et al. Alpha-1-antitrypsin deficiency in children: clinical characteristics and diagnosis. Srp Arh Celok Lek. 2014;142:547\u201350.","journal-title":"Srp Arh Celok Lek"},{"key":"856_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0022-3468(00)80003-2","volume":"35","author":"L Migliazza","year":"2000","unstructured":"Migliazza L, L\u00f3pez Santamar\u00eda M, Murcia J, Gamez M, Clavijo J, Camarena C, et al. Long-term survival expectancy after liver transplantation in children. J Pediatr Surg. 2000;35:5\u20137.","journal-title":"J Pediatr Surg"},{"key":"856_CR27","first-page":"1851","volume":"111","author":"SA Townsend","year":"2018","unstructured":"Townsend SA, Edgar RG, Ellis PR, Kantas D, Newsome PN, Turner AM. Systematic review: the natural history of alpha-1 antitrypsin deficiency and associated liver disease. Aliment Pharmacol Ther. 2018;111:1851.","journal-title":"Aliment Pharmacol Ther"},{"key":"856_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM197606102942404","volume":"294","author":"T Sveger","year":"1976","unstructured":"Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294:1316\u201321.","journal-title":"N Engl J Med"},{"key":"856_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MPG.0000000000000196","volume":"58","author":"J Teckman","year":"2014","unstructured":"Teckman J, Pardee E, Howell RR, Mannino D, Sharp RR, Brantly M, et al. Appropriateness of newborn screening for \u03b11-antitrypsin deficiency. J Pediatr Gastroenterol Nutr. 2014;58:199\u2013203.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"856_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1651-2227.1988.tb10767.x","volume":"77","author":"T Sveger","year":"1988","unstructured":"Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand. 1988;77:847\u201351.","journal-title":"Acta Paediatr Scand"},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","volume":"50","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in \u03b11-antitrypsin deficiency. Eur Respir J. 2017;50:1700610.","journal-title":"Eur Respir J"},{"key":"856_CR32","first-page":"668","volume":"3","author":"RA Sandhaus","year":"2016","unstructured":"Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3:668\u201382.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"856_CR33","first-page":"128","volume":"53","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Mart\u00ednez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53:128\u201349.","journal-title":"Arch Bronconeumol"},{"key":"856_CR34","first-page":"324","volume":"53","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Soler-Catalu\u00f1a JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017 Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53:324\u201335.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"856_CR35","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1513\/AnnalsATS.201506-349KV","volume":"13","author":"JK Stoller","year":"2016","unstructured":"Stoller JK. Detecting alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(4):S317\u201325.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1378\/chest.128.3.1179","volume":"128","author":"MA Campos","year":"2005","unstructured":"Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128:1179\u201386.","journal-title":"Chest"},{"key":"856_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00010614","volume":"24","author":"J Chorostowska-Wynimko","year":"2015","unstructured":"Chorostowska-Wynimko J. Targeted screening programmes in COPD: how to identify individuals with \u03b11-antitrypsin deficiency. Eur Respir Rev. 2015;24:40\u20135.","journal-title":"Eur Respir Rev"},{"key":"856_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.arbres.2014.05.008","volume":"51","author":"F Casas","year":"2015","unstructured":"Casas F, Blanco I, Mart\u00ednez MT, Bustamante A, Miravitlles M, Cadenas S, et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. Arch Bronconeumol. 2015;51:185\u201392.","journal-title":"Arch Bronconeumol"},{"key":"856_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1164\/rccm.168.7.818","volume":"168","author":"American Thoracic Society","year":"2003","unstructured":"American Thoracic Society. European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818\u2013900.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2500\/aap.2017.38.4031","volume":"38","author":"F Kueppers","year":"2017","unstructured":"Kueppers F, Sanders C. State-of-the-art testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38:108\u201314.","journal-title":"Allergy Asthma Proc"},{"key":"856_CR41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1651-2227.1996.tb18230.x","volume":"85","author":"T Thelin","year":"1996","unstructured":"Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr. 1996;85:1207\u201312.","journal-title":"Acta Paediatr"},{"key":"856_CR42","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1097\/MPG.0000000000000720","volume":"60","author":"JT Tretter","year":"2015","unstructured":"Tretter JT. Adding \u03b1-1 antitrypsin deficiency to the newborn screen. J Pediatr Gastroenterol Nutr. 2015;60:e37.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"856_CR43","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/MPG.0000000000000721","volume":"60","author":"J Teckman","year":"2015","unstructured":"Teckman J. Author's response. J Pediatr Gastroenterol Nutr. 2015;60:e38.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"856_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/crj.12310","volume":"11","author":"T Greulich","year":"2017","unstructured":"Greulich T, Averyanov A, Borsa L, Rozborilov\u00e1 E, Vaicius D, Major T, et al. European screening for alpha-1-antitrypsin deficiency in subjects with lung disease. Clin Respir J. 2017;11:90\u20137.","journal-title":"Clin Respir J"},{"key":"856_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1753465815602162","volume":"10","author":"T Greulich","year":"2016","unstructured":"Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10:72\u201384.","journal-title":"Ther Adv Respir Dis"},{"key":"856_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1183\/09059180.10010814","volume":"24","author":"NG McElvaney","year":"2015","unstructured":"McElvaney NG. Diagnosing \u03b11-antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev. 2015;24:52\u20137.","journal-title":"Eur Respir Rev"},{"key":"856_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1183\/09031936.00104712","volume":"42","author":"B Piras","year":"2013","unstructured":"Piras B, Ferrarotti I, Lara B, Mart\u00ednez MT, Bustamante A, Ottaviani S, et al. Clinical phenotypes of Italian and Spanish patients with \u03b11-antitrypsin deficiency. Eur Respir J. 2013;42:54\u201364.","journal-title":"Eur Respir J"},{"key":"856_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arbres.2015.04.001","volume":"52","author":"M Miravitlles","year":"2016","unstructured":"Miravitlles M. What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved? Arch Bronconeumol. 2016;52:1\u20132.","journal-title":"Arch Bronconeumol"},{"key":"856_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3399\/bjgp17X690389","volume":"67","author":"A Fern\u00e1ndez-Villar","year":"2017","unstructured":"Fern\u00e1ndez-Villar A, Soriano JB, L\u00f3pez-Campos JL. Overdiagnosis of COPD: precise definitions and proposals for improvement. Br J Gen Pract. 2017;67:183\u20134.","journal-title":"Br J Gen Pract"},{"key":"856_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1183\/09031936.00168113","volume":"44","author":"G Thabut","year":"2014","unstructured":"Thabut G, Mornex J-F, Pison C, Cuvelier A, Balduyck M, Pujazon M-C, et al. Performance of the BODE index in patients with \u03b11-antitrypsin deficiency-related COPD. Eur Respir J. 2014;44:78\u201386.","journal-title":"Eur Respir J"},{"key":"856_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3109\/15412555.2014.898030","volume":"11","author":"S Manca","year":"2014","unstructured":"Manca S, Rodr\u00edguez E, Huerta A, Torres M, L\u00e1zaro L, Curi S, et al. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. COPD. 2014;11:480\u20138.","journal-title":"COPD."},{"key":"856_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1465-9921-11-44","volume":"11","author":"HA Tanash","year":"2010","unstructured":"Tanash HA, Nilsson PM, Nilsson J-A, Piitulainen E. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res. 2010;11:44.","journal-title":"Respir Res"},{"key":"856_CR53","first-page":"1196","volume":"127","author":"JK Stoller","year":"2005","unstructured":"Stoller JK, Tomashefski J, Crystal RG, Arroliga A, Strange C, Killian DN, et al. Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute registry. Chest. 2005;127:1196\u2013204.","journal-title":"Chest"},{"key":"856_CR54","first-page":"1091","volume":"63","author":"HA Tanash","year":"2008","unstructured":"Tanash HA, Nilsson PM, Nilsson J-A, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax BMJ Publishing Group Ltd and British Thoracic Society. 2008;63:1091\u20135.","journal-title":"Thorax BMJ Publishing Group Ltd and British Thoracic Society"},{"key":"856_CR55","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1373\/clinchem.2006.078907","volume":"52","author":"M Brantly","year":"2006","unstructured":"Brantly M. Efficient and accurate approaches to the laboratory diagnosis of alpha1-antitrypsin deficiency: the promise of early diagnosis and intervention. Clin Chem. 2006;52:2180\u20131.","journal-title":"Clin Chem"},{"key":"856_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1164\/rccm.201311-1984OC","volume":"189","author":"K Molloy","year":"2014","unstructured":"Molloy K, Hersh CP, Morris VB, Carroll TP, OConnor CA, Lasky-Su JA, et al. Clarification of the risk of chronic obstructive pulmonary disease in \u03b11-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189:419\u201327.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"856_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15412555.2015.1021913","volume":"12","author":"ME O'Brien","year":"2015","unstructured":"O'Brien ME, Pennycooke K, Carroll TP, Shum J, Fee LT, O'Connor C, et al. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease. COPD. 2015;12(1):2\u20139.","journal-title":"COPD"},{"key":"856_CR58","first-page":"485","volume":"1","author":"AS Mayer","year":"2006","unstructured":"Mayer AS, Stoller JK, Vedal S, Ruttenber AJ, Strand M, Sandhaus RA, et al. Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2006;1:485\u201392.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"856_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/15412555.2015.1021909","volume":"12","author":"E Piitulainen","year":"2015","unstructured":"Piitulainen E, Tanash HA. The clinical profile of subjects included in the Swedish national register on individuals with severe alpha 1-antitrypsin deficiency. COPD. 2015;12(1):36\u201341.","journal-title":"COPD"},{"key":"856_CR60","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.rmed.2008.12.021","volume":"103","author":"E Bernsp\u00e5ng","year":"2009","unstructured":"Bernsp\u00e5ng E, Wollmer P, Sveger T, Piitulainen E. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals. Respir Med. 2009;103:861\u20135.","journal-title":"Respir Med"},{"key":"856_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1183\/09031936.99.13224799","volume":"13","author":"E Piitulainen","year":"1999","unstructured":"Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13:247\u201351.","journal-title":"Eur Respir J"},{"key":"856_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1164\/ajrccm.158.1.9712017","volume":"158","author":"The\u2002Alpha-1-Antitrypsin\u2002Deficiency\u2002Registry\u2002Study\u2002Group *","year":"1998","unstructured":"The\u2002Alpha-1-Antitrypsin\u2002Deficiency\u2002Registry\u2002Study\u2002Group *. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin The alpha-1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med. 1998;158:49\u201359.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR63","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thoraxjnl-2015-206906","volume":"70","author":"CE Green","year":"2015","unstructured":"Green CE, Vayalapra S, Hampson JA, Mukherjee D, Stockley RA, Turner AM. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax. 2015;70:939\u201345.","journal-title":"Thorax"},{"key":"856_CR64","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/thx.2004.022541","volume":"59","author":"CP Hersh","year":"2004","unstructured":"Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59:843\u20139.","journal-title":"Thorax"},{"issue":"Suppl 4","key":"856_CR65","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1513\/AnnalsATS.201507-437KV","volume":"13","author":"EK Silverman","year":"2016","unstructured":"Silverman EK. Risk of lung disease in PI MZ heterozygotes. Current status and future research directions. Ann Am Thorac Soc. 2016;13(Suppl 4):S341\u20135.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR66","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1378\/chest.10-0746","volume":"138","author":"I-C S\u00f8rheim","year":"2010","unstructured":"S\u00f8rheim I-C, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, et al. \u03b11-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest. 2010;138:1125\u201332.","journal-title":"Chest"},{"key":"856_CR67","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/lt.23744","volume":"19","author":"EJ Carey","year":"2013","unstructured":"Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. Liver Transpl. 2013;19:1370\u20136.","journal-title":"Liver Transpl"},{"key":"856_CR68","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/lt.24434","volume":"22","author":"AS Chu","year":"2016","unstructured":"Chu AS, Chopra KB, Perlmutter DH. Is severe progressive liver disease caused by alpha-1-antitrypsin deficiency more common in children or adults? Liver Transpl. 2016;22:886\u201394.","journal-title":"Liver Transpl"},{"key":"856_CR69","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1164\/arrd.1977.116.3.469","volume":"116","author":"RM Senior","year":"1977","unstructured":"Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis. 1977;116:469\u201375.","journal-title":"Am Rev Respir Dis"},{"key":"856_CR70","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1183\/09031936.97.10102260","volume":"10","author":"N Seersholm","year":"1997","unstructured":"Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study Group. Eur Respir J. 1997;10:2260\u20133.","journal-title":"Eur Respir J"},{"key":"856_CR71","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1378\/chest.119.3.737","volume":"119","author":"M Wencker","year":"2001","unstructured":"Wencker M, Fuhrmann B, Banik N, Konietzko N. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119:737\u201344.","journal-title":"Chest"},{"key":"856_CR72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/COPD.S8577","volume":"4","author":"AR Tonelli","year":"2009","unstructured":"Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"856_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1750-1172-8-149","volume":"8","author":"M Miravitlles","year":"2013","unstructured":"Stockley RA, Miravitlles M, Vogelmeier C. Alpha one international registry (a.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149.","journal-title":"Orphanet J Rare Dis"},{"key":"856_CR74","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","volume":"316","author":"MD Wewers","year":"1987","unstructured":"Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med Massachusetts Medical Society. 1987;316:1055\u201362.","journal-title":"N Engl J Med Massachusetts Medical Society"},{"key":"856_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1155\/2012\/920918","volume":"19","author":"DD Marciniuk","year":"2012","unstructured":"Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian thoracic society clinical practice guideline. Can Respir J. 2012;19:109\u201316.","journal-title":"Can Respir J"},{"key":"856_CR76","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","volume":"160","author":"A Dirksen","year":"1999","unstructured":"Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.rmed.2012.12.003","volume":"107","author":"J Holme","year":"2013","unstructured":"Holme J, Stockley JA, Stockley RA. Age related development of respiratory abnormalities in non-index \u03b1-1 antitrypsin deficient studies. Respir Med. 2013;107:387\u201393.","journal-title":"Respir Med"},{"key":"856_CR78","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1183\/09031936.00061208","volume":"33","author":"PA Dawkins","year":"2009","unstructured":"Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33:1338\u201344.","journal-title":"Eur Respir J"},{"key":"856_CR79","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1183\/09031936.01.00056501","volume":"17","author":"LJ Dowson","year":"2001","unstructured":"Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17:1097\u2013104.","journal-title":"Eur Respir J"},{"key":"856_CR80","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1183\/09031936.00159408","volume":"33","author":"A Dirksen","year":"2009","unstructured":"Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33:1345\u201353.","journal-title":"Eur Respir J"},{"key":"856_CR81","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1465-9921-11-136","volume":"11","author":"RA Stockley","year":"2010","unstructured":"Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of \u03b1-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136.","journal-title":"Respir Res"},{"key":"856_CR82","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/15412550902905961","volume":"6","author":"KR Chapman","year":"2009","unstructured":"Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6:177\u201384.","journal-title":"COPD"},{"key":"856_CR83","first-page":"CD007851","volume-title":"Cochrane Database Syst Rev","author":"PC G\u00f8tzsche","year":"2010","unstructured":"G\u00f8tzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. In: G\u00f8tzsche PC, editor. Cochrane Database Syst Rev. Chichester: Wiley; 2010. p. CD007851."},{"key":"856_CR84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","volume":"386","author":"KR Chapman","year":"2015","unstructured":"Chapman KR, Burdon JGW, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360\u20138.","journal-title":"Lancet"},{"key":"856_CR85","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","volume":"5","author":"NG McElvaney","year":"2017","unstructured":"McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PAB, Thompson PJ, et al. Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5:51\u201360.","journal-title":"Lancet Respir Med"},{"key":"856_CR86","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1378\/chest.118.5.1480","volume":"118","author":"J Lieberman","year":"2000","unstructured":"Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118:1480\u20135.","journal-title":"Chest"},{"key":"856_CR87","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1164\/rccm.2109013","volume":"165","author":"RA Stockley","year":"2002","unstructured":"Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/1753465812438387","volume":"6","author":"JC Barros-Tiz\u00f3n","year":"2012","unstructured":"Barros-Tiz\u00f3n JC, Torres ML, Blanco I, Mart\u00ednez MT. Investigators of the rEXA study group. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis. 2012;6:67\u201378.","journal-title":"Ther Adv Respir Dis"},{"key":"856_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.1787609","volume":"23","author":"SL Berger","year":"2009","unstructured":"Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781\u20133.","journal-title":"Genes Dev"},{"key":"856_CR90","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4161\/epi.20319","volume":"7","author":"M Siedlinski","year":"2012","unstructured":"Siedlinski M, Klanderman B, Sandhaus RA, Barker AF, Brantly ML, Eden E, et al. Association of cigarette smoking and CRP levels with DNA methylation in \u03b1-1 antitrypsin deficiency. Epigenetics. 2012;7:720\u20138.","journal-title":"Epigenetics"},{"key":"856_CR91","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1164\/rccm.201108-1382OC","volume":"185","author":"W Qiu","year":"2012","unstructured":"Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med. 2012;185:373\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR92","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/BF01534484","volume":"13","author":"DE Barton","year":"1987","unstructured":"Barton DE, Francke U. Activation of human alpha 1-antitrypsin genes in rat hepatoma x human fibroblast hybrid cell lines is correlated with demethylation. Somat Cell Mol Genet. 1987;13:635\u201344.","journal-title":"Somat Cell Mol Genet"},{"key":"856_CR93","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1164\/rccm.201306-1151OC","volume":"189","author":"T Hassan","year":"2014","unstructured":"Hassan T, Carroll TP, Buckley PG, Cummins R, ONeill SJ, McElvaney NG, et al. miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and \u03b11-antitrypsin deficiency. Am J Respir Crit Care Med. 2014;189:263\u201373.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR94","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1164\/rccm.201312-2230ED","volume":"189","author":"SP Nana-Sinkam","year":"2014","unstructured":"Nana-Sinkam SP, Choi AMK. Epigenetics and the unfolded protein response in the lung: emerging role for microRNAs. Am J Respir Crit Care Med. 2014;189:239\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"856_CR95","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.2147\/COPD.S145445","volume":"12","author":"C Esquinas","year":"2017","unstructured":"Esquinas C, Janciauskiene S, Gonzalo R, Mas de Xaxars G, Olejnicka B, Belmonte I, et al. Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2017;12:3381\u201390.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"856_CR96","doi-asserted-by":"publisher","first-page":"38265","DOI":"10.1074\/jbc.M112.404707","volume":"287","author":"M Bouchecareilh","year":"2012","unstructured":"Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of \u03b11-antitrypsin deficiency. J Bio Chem. 2012;287:38265\u201378.","journal-title":"J Bio Chem"},{"key":"856_CR97","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/thoraxjnl-2014-205898","volume":"70","author":"A Escribano","year":"2015","unstructured":"Escribano A, Amor M, Pastor S, Castillo S, Sanz F, Codoner-Franch P, et al. Decreased glutathione and low catalase activity contribute to oxidative stress in children with \u03b1-1 antitrypsin deficiency. Thorax. 2015;70:82\u20133.","journal-title":"Thorax"},{"key":"856_CR98","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1183\/13993003.00176-2016","volume":"48","author":"A Escribano","year":"2016","unstructured":"Escribano A, Pastor S, Reula A, Castillo S, Vicente S, Sanz F, et al. Accelerated telomere attrition in children and teenagers with \u03b11-antitrypsin deficiency. Eur Respir J. 2016;48:350\u20138.","journal-title":"Eur Respir J"},{"key":"856_CR99","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1165\/rcmb.2010-0328OC","volume":"45","author":"S Alam","year":"2011","unstructured":"Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z \u03b11-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol. 2011;45:261\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"856_CR100","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/hmg\/ddv501","volume":"25","author":"R Ronzoni","year":"2016","unstructured":"Ronzoni R, Berardelli R, Medicina D, Sitia R, Gooptu B, Fra AM. Aberrant disulphide bonding contributes to the ER retention of alpha1-antitrypsin deficiency variants. Hum Mol Genet. 2016;25:642\u201350.","journal-title":"Hum Mol Genet"},{"key":"856_CR101","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1651-2227.1993.tb12647.x","volume":"82","author":"K Pittschieler","year":"1993","unstructured":"Pittschieler K. Vitamin E and liver damage in MZ heterozygous infants with alpha 1-antitrypsin deficiency. Acta Paediatr. 1993;82:228\u201332.","journal-title":"Acta Paediatr"},{"key":"856_CR102","doi-asserted-by":"publisher","first-page":"L478","DOI":"10.1152\/ajplung.00361.2007","volume":"294","author":"A Kode","year":"2008","unstructured":"Kode A, Rajendrasozhan S, Caito S, Yang S-R, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294:L478\u201388.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"856_CR103","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1165\/ajrcmb.20.3.3144","volume":"20","author":"A Novoradovsky","year":"1999","unstructured":"Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol. 1999;20:441\u20137.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"856_CR104","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1378\/chest.127.5.1537","volume":"127","author":"F Rodriguez","year":"2005","unstructured":"Rodriguez F, la Roza de C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest. 2005;127:1537\u201343.","journal-title":"Chest"},{"issue":"5","key":"856_CR105","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10528-016-9748-7","volume":"54","author":"A Topic","year":"2016","unstructured":"Topic A, Nagorni-Obradovic L, Francuski D, Ljujic M, Malic Z, Radojkovic D. Oxidative stress and polymorphism of xenobiotic-metabolizing enzymes in two patients with severe Alpha-1-antitrypsin deficiency. Biochem Genet. 2016;54(5):746\u201352.","journal-title":"Biochem Genet"},{"key":"856_CR106","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1465-9921-9-52","volume":"9","author":"AM Wood","year":"2008","unstructured":"Wood AM, Simmonds MJ, Bayley DL, Newby PR, Gough SC, Stockley RA. The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency. Respir Res. 2008;9:52.","journal-title":"Respir Res"},{"key":"856_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1165\/rcmb.2007-0107OC","volume":"38","author":"DL Demeo","year":"2008","unstructured":"Demeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, et al. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol. 2008;38:114\u201320.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"856_CR108","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1465-9921-13-16","volume":"13","author":"WJ Kim","year":"2012","unstructured":"Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res. 2012;13:16.","journal-title":"Respir Res"},{"issue":"4","key":"856_CR109","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1513\/AnnalsATS.201509-574KV","volume":"13","author":"GM Turino","year":"2016","unstructured":"Turino GM, Ma S, Cantor JO, Lin YY. Biomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(4):S336\u201340.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR110","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1378\/chest.128.4.2076","volume":"128","author":"E Piitulainen","year":"2005","unstructured":"Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease\/protease inhibitor studies. Chest. 2005;128:2076\u201381.","journal-title":"Chest"},{"key":"856_CR111","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/15412551003631733","volume":"7","author":"J Holme","year":"2010","unstructured":"Holme J, Dawkins PA, Stockley EK, Parr DG, Stockley RA. Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. COPD. 2010;7:126\u201332.","journal-title":"COPD"},{"key":"856_CR112","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1378\/chest.06-2251","volume":"131","author":"S Ma","year":"2007","unstructured":"Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest. 2007;131:1363\u201371.","journal-title":"Chest"},{"key":"856_CR113","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1183\/09031936.00174807","volume":"32","author":"M Luisetti","year":"2008","unstructured":"Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J. 2008;32:1146\u201357.","journal-title":"Eur Respir J"},{"key":"856_CR114","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000196395","volume":"62","author":"PJ Stone","year":"1995","unstructured":"Stone PJ, Morris TA, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans. Respiration. 1995;62:76\u20139.","journal-title":"Respiration"},{"issue":"4","key":"856_CR115","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1513\/AnnalsATS.201506-348KV","volume":"13","author":"DA Lomas","year":"2016","unstructured":"Lomas DA. An ECLIPSE view of alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(4):S326\u201331.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR116","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/thoraxjnl-2012-201871","volume":"68","author":"A Duvoix","year":"2013","unstructured":"Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68:670\u20136.","journal-title":"Thorax"},{"key":"856_CR117","doi-asserted-by":"publisher","first-page":"23","DOI":"10.15326\/jcopdf.2.1.2014.0138","volume":"2","author":"DM Mannino","year":"2015","unstructured":"Mannino DM, Tal-Singer R, Lomas DA, Vestbo J, Graham Barr R, Tetzlaff K, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. COPD. 2015;2:23\u201334.","journal-title":"COPD"},{"key":"856_CR118","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/thx.2010.154690","volume":"66","author":"RI Carter","year":"2011","unstructured":"Carter RI, Mumford RA, Treonze KM, Finke PE, Davies P, Si Q, et al. The fibrinogen cleavage product A\u03b1-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax. 2011;66:686\u201391.","journal-title":"Thorax"},{"key":"856_CR119","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1378\/chest.14-0520","volume":"148","author":"RI Carter","year":"2015","unstructured":"Carter RI, Ungurs MJ, Pillai A, Mumford RA, Stockley RA. The relationship of the fibrinogen cleavage biomarker A\u03b1-Val360 with disease severity and activity in \u03b11-antitrypsin deficiency. Chest. 2015;148:382\u20138.","journal-title":"Chest"},{"key":"856_CR120","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1183\/09031936.00212011","volume":"41","author":"H Rupani","year":"2013","unstructured":"Rupani H, Sanchez-Elsner T, Howarth P. MicroRNAs and respiratory diseases. Eur Respir J. 2013;41:695\u2013705.","journal-title":"Eur Respir J"},{"key":"856_CR121","doi-asserted-by":"publisher","first-page":"9853","DOI":"10.3748\/wjg.v21.i34.9853","volume":"21","author":"Y-C Zhang","year":"2015","unstructured":"Zhang Y-C, Xu Z, Zhang T-F, Wang Y-L. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol. 2015;21:9853\u201362.","journal-title":"World J Gastroenterol"},{"key":"856_CR122","first-page":"2038","volume":"44","author":"F Dasi","year":"2014","unstructured":"Dasi F, Pastor S, Mata M, Amor M, Serna E, Castillo S, et al. Circulating microRNAs as potential biomarkers in alpha-1 antitrypsin deficiency patients. Eur Respir J. 2014;44:2038.","journal-title":"Eur Respir J"},{"key":"856_CR123","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.molmed.2013.10.007","volume":"20","author":"B Gooptu","year":"2014","unstructured":"Gooptu B, Dickens JA, Lomas DA. The molecular and cellular pathology of \u03b11-antitrypsin deficiency. Trends Mol Med. 2014;20:116\u201327.","journal-title":"Trends Mol Med"},{"key":"856_CR124","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-4939-7163-3_27","volume":"1639","author":"AM Gruntman","year":"2017","unstructured":"Gruntman AM, Flotte TR. Therapeutics: gene therapy for alpha-1 antitrypsin deficiency. Methods Mol Biol. 2017;1639:267\u201375.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"856_CR125","doi-asserted-by":"publisher","first-page":"S346","DOI":"10.1513\/AnnalsATS.201507-469KV","volume":"13","author":"M Griese","year":"2016","unstructured":"Griese M, Scheuch G. Delivery of Alpha-1 antitrypsin to airways. Ann Am Thorac Soc. 2016;13(4):S346\u201351.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"856_CR126","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1513\/AnnalsATS.201506-344KV","volume":"13","author":"MJ Chiuchiolo","year":"2016","unstructured":"Chiuchiolo MJ, Crystal RG. Gene therapy for alpha-1 antitrypsin deficiency lung disease. Ann Am Thorac Soc. 2016;13(4):S352\u201369.","journal-title":"Ann Am Thorac Soc"},{"key":"856_CR127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s001090000185","volume":"79","author":"F Das\u00ed","year":"2001","unstructured":"Das\u00ed F, Benet M, Crespo J, Crespo A, Ali\u00f1o SF. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med. 2001;79:205\u201312.","journal-title":"J Mol Med"},{"key":"856_CR128","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/sj.gt.3302065","volume":"10","author":"SF Ali\u00f1o","year":"2003","unstructured":"Ali\u00f1o SF, Crespo A, Das\u00ed F. Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA. Gene Ther. 2003;10:1672\u20139.","journal-title":"Gene Ther"},{"key":"856_CR129","doi-asserted-by":"publisher","first-page":"14258","DOI":"10.1073\/pnas.1109522108","volume":"108","author":"C Li","year":"2011","unstructured":"Li C, Xiao P, Gray SJ, Weinberg MS, Samulski RJ. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A. 2011;108:14258\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"856_CR130","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/mt.2011.292","volume":"20","author":"C Mueller","year":"2012","unstructured":"Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. 2012;20:590\u2013600.","journal-title":"Mol Ther"},{"key":"856_CR131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1165\/rcmb.2016-0301PS","volume":"56","author":"D Alapati","year":"2017","unstructured":"Alapati D, Morrisey EE. Gene editing and genetic lung disease. Basic research meets therapeutic application. Am J Respir Cell Mol Biol. 2017;56:283\u201390.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"856_CR132","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1517\/14712598.2015.994501","volume":"15","author":"R Barrangou","year":"2015","unstructured":"Barrangou R, May AP. Unraveling the potential of CRISPR-Cas9 for gene therapy. Expert Opin Biol Ther. 2015;15:311\u20134.","journal-title":"Expert Opin Biol Ther"},{"key":"856_CR133","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nmeth.4293","volume":"14","author":"KA Schaefer","year":"2017","unstructured":"Schaefer KA, Wu W-H, Colgan DF, Tsang SH, Bassuk AG, Mahajan VB. Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat Methods. 2017;14:547\u20138.","journal-title":"Nat Methods"},{"key":"856_CR134","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","volume":"63","author":"J Tycko","year":"2016","unstructured":"Tycko J, Myer VE, Hsu PD. Methods for ptimizing CRISPR-Cas9 genome editing specificity. Mol Cell. 2016;63:355\u201370.","journal-title":"Mol Cell"},{"key":"856_CR135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gr.162339.113","volume":"24","author":"SW Cho","year":"2014","unstructured":"Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, et al. Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014;24:132\u201341.","journal-title":"Genome Res"},{"key":"856_CR136","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1172\/JCI45260","volume":"121","author":"J Ding","year":"2011","unstructured":"Ding J, Yannam GR, Roy-Chowdhury N, Hidvegi T, Basma H, Rennard SI, et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human \u03b11-antitrypsin by wild-type donor hepatocytes. J Clin Invest. 2011;121:1930\u20134.","journal-title":"J Clin Invest"},{"key":"856_CR137","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1172\/JCI43122","volume":"120","author":"ST Rashid","year":"2010","unstructured":"Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest. 2010;120:3127\u201336.","journal-title":"J Clin Invest"},{"key":"856_CR138","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature10424","volume":"478","author":"K Yusa","year":"2011","unstructured":"Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu P-Q, Paschon DE, et al. Targeted gene correction of \u03b11-antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011;478:391\u20134.","journal-title":"Nature"},{"key":"856_CR139","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1021\/jm070687z","volume":"50","author":"M Mallya","year":"2007","unstructured":"Mallya M, Phillips RL, Saldanha SA, Gooptu B, Brown SCL, Termine DJ, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem. 2007;50:5357\u201363.","journal-title":"J Med Chem"},{"key":"856_CR140","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jpeds.2013.03.077","volume":"163","author":"GA Silverman","year":"2013","unstructured":"Silverman GA, Pak SC, Perlmutter DH. Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype. J Pediatr. 2013;163:320\u20136.","journal-title":"J Pediatr"},{"key":"856_CR141","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1074\/jbc.C100722200","volume":"277","author":"R Mahadeva","year":"2002","unstructured":"Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem. 2002;277:6771\u20134.","journal-title":"J Biol Chem"},{"key":"856_CR142","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1126\/science.1190354","volume":"329","author":"T Hidvegi","year":"2010","unstructured":"Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329:229\u201332.","journal-title":"Science"},{"key":"856_CR143","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1258\/ebm.2010.009297","volume":"235","author":"S Kaushal","year":"2010","unstructured":"Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood). 2010;235:700\u20139.","journal-title":"Exp Biol Med (Maywood)"},{"key":"856_CR144","first-page":"446","volume":"12","author":"DH Perlmutter","year":"2016","unstructured":"Perlmutter DH. Current and emerging treatments for alpha-1 antitrypsin deficiency. Gastroenterol Hepatol (N Y). 2016;12:446\u20138.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0856-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T16:45:47Z","timestamp":1568997947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0856-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0856-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"5 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. Mar\u00eda Torres-Dur\u00e1n, Silvia Castillo, Amparo Escribano, Mar\u00eda Mercedes Navarro Garc\u00eda, Daniel Pellicer, Luc\u00eda Ba\u00f1uls, Francisco Casas and Francisco Das\u00ed report no disclosures.Dr. Jos\u00e9 Luis L\u00f3pez-Campos reports personal fees and non-financial support from Grifols, during the conduct of the study.Dr. Miriam Barrecheguren reports personal fees from Menarini, personal fees from GlaxoSmithKline, personal fees from Gebro pharme, personal fees from Novartis, personal fees from Grifols, outside the submitted work.Dr. Miravitlles reports personal fees from Boehringer Ingelheim, AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Teva, Grifols and Novartis, personal fees from Bayer Schering, Boehringer Ingelheim, GlaxoSmithKline, Gebro Pharma, CLS Behring, Cipla, MediImmune, Mereo Biopharma, Teva, Novartis and Grifols, outside the submitted work.Dr. Martinez-Delgado reports grants from Ministerio de Econom\u00eda y Competitividad. ISCIII. (Spain), other from Registro Espa\u00f1ol de pacientes con Deficit de alfa-1 antitripsina (REDAAT). Fundaci\u00f3n Espa\u00f1ola de Pulm\u00f3n, during the conduct of the study.Dr. Baloira reports personal fees and non-financial support from GRIFOLS during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"114"}}